ForPatients
by Roche

Rheumatoid Arthritis

An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis

Trial Status	Trial Runs In	Trial Identifier
Recruiting	3 Countries	NCT07620392 2025-523579-47-00,2025 WA46440

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The study will evaluate the long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with moderate to severe Rheumatoid Arthritis (RA) who have an inadequate response or intolerance to tumor necrosis factor (TNF) and/or Janus kinase (JAK) inhibitors, and who were previously treated with Afimkibart.

Hoffmann-La Roche Sponsor	**Phase 2** Phase

NCT07620392 2025-523579-47-00,2025 WA46440
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=18 Years	No

© 2022 F. Hoffmann-La Roche Ltd